Exonate Overview
- Year Founded
-
2013

- Status
-
Private
- Employees
-
15

- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$1.9M
- Investors
-
19
Exonate General Information
Description
Developer of a biopharmaceutical drug designed to improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss. The company offers program molecules, for wet age-related macular degeneration (wet AMD), which act via a novel mechanism of action to inhibit pathological blood vessels and reduce the formation of pathological vascular endothelial growth factor without inhibiting beneficial, non-pathological vascular endothelial growth factor (VEGF), helping doctors to focus on developing novel therapies for wet age-related macular degeneration.
Contact Information
Website
www.exonate.comCorporate Office
- WTL Moorfield Road, Duxford
- Cambridgeshire
- Cambridge CB22 4PS
- England, United Kingdom
Corporate Office
- WTL Moorfield Road, Duxford
- Cambridgeshire
- Cambridge CB22 4PS
- England, United Kingdom
Exonate Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Later Stage VC (Series A) | 03-Jan-2019 | $1.9M | Completed | Clinical Trials - Phase 2 | ||
6. Later Stage VC | 12-Sep-2018 | Completed | Clinical Trials - Phase 1 | |||
5. Grant | 06-Feb-2017 | Completed | Clinical Trials - Phase 1 | |||
4. Early Stage VC | 01-Dec-2016 | Completed | Clinical Trials - Phase 1 | |||
3. Early Stage VC | 05-Oct-2015 | Completed | Clinical Trials - Phase 1 | |||
2. Seed Round | 01-Mar-2014 | $651K | $651K | Completed | Clinical Trials - Phase 1 | |
1. University Spin-Out | 01-Jan-2013 | Completed | Startup |
Exonate Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | ||||||||
Ordinary | ||||||||
Ordinary | 14,141 | $0.012877 | $72.11 | $72.11 | 1x | $72.11 | 17.79% | |
Ordinary | 7,860 | $0.012877 | $64.39 | $64.39 | 1x | $64.39 | 9.89% |
Exonate Comparisons
Industry
Financing
Details
Exonate Competitors (28)
One of Exonate’s 28 competitors is Oxular, a Formerly VC-backed company based in London, United Kingdom.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Oxular | Formerly VC-backed | London, United Kingdom | ||||
TearSolutions | Venture Capital-Backed | Charlottesville, VA | ||||
Allegro Ophthalmics | Venture Capital-Backed | San Juan Capistrano, CA | ||||
Kala Bio | Formerly VC-backed | Arlington, MA | ||||
Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Exonate Patents
Exonate Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3183466-A1 | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | Pending | 14-Jul-2020 | ||
AU-2021309894-A1 | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | Pending | 14-Jul-2020 | ||
US-20220411412-A1 | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | Active | 14-Jul-2020 | ||
EP-4182311-A1 | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | Active | 14-Jul-2020 | ||
GB-202010829-D0 | Compounds for treatment of neovascular diseases | Inactive | 14-Jul-2020 | C07D405/14 |
Exonate Signals
Exonate Investors (19)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
EMV Capital | Venture Capital | Minority | ||
Stoic Venture Capital | Venture Capital | Minority | ||
University of Bristol Endowment | Limited Partner | Minority | ||
R42 Group | Venture Capital | Minority | ||
Wellcome Trust | Limited Partner |
Exonate FAQs
-
When was Exonate founded?
Exonate was founded in 2013.
-
Where is Exonate headquartered?
Exonate is headquartered in Cambridge, United Kingdom.
-
What is the size of Exonate?
Exonate has 15 total employees.
-
What industry is Exonate in?
Exonate’s primary industry is Drug Discovery.
-
Is Exonate a private or public company?
Exonate is a Private company.
-
What is Exonate’s current revenue?
The current revenue for Exonate is
. -
How much funding has Exonate raised over time?
Exonate has raised $7.74M.
-
Who are Exonate’s investors?
EMV Capital, Stoic Venture Capital, University of Bristol Endowment, R42 Group, and Wellcome Trust are 5 of 19 investors who have invested in Exonate.
-
Who are Exonate’s competitors?
Oxular, TearSolutions, Allegro Ophthalmics, Kala Bio, and Alnylam Pharmaceuticals are some of the 28 competitors of Exonate.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »